Axsome Therapeutics Inc
NASDAQ:AXSM

  • LAST PRICE
    99.4900
  • TODAY'S CHANGE (%)
    8.5100 (9.3537%)
  • Bid / Lots
    99.0000/ 1
  • Ask / Lots
    99.5000/ 5
  • Open / Previous Close
    95.0000 / 90.9800
  • Day Range
    92.2053
    101.5050
  • 52 Week Range
    55.0200
    101.5050
  • Volume
    1,564,783

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
AXSM
Axsome Therapeutics Inc
4.4B
-15.3x
---
DNLI
Denali Therapeutics Inc
4.5B
-10.8x
---
TGTX
TG Therapeutics Inc
4.8B
-289.7x
---
CRSP
CRISPR Therapeutics AG
4.7B
-18.1x
---
ADMA
ADMA Biologics Inc
5.3B
154.9x
---
ZLAB
Zai Lab Ltd
3.2B
-9.4x
---
As of 2024-11-12

Company Information

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

Contact Information

Headquarters
One World Trade Center, 22Nd FloorNEW YORK, NY, United States 10007
Phone
212-332-3241
Fax
212-320-0245

Executives

Chairman of the Board, Chief Executive Officer, Founder, Interim Principal Financial Officer
Herriot Tabuteau
Chief Financial Officer
Nick Pizzie
Chief Operating Officer
Mark Jacobson
Executive Vice President - Product Strategy
Lori Englebert
Executive Vice President - Head of Commercial
Ari Maizel

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$4.4B
Revenue (TTM)
$291.5M
Shares Outstanding
48.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.16
EPS
$-6.51
Book Value
$4.03
P/E Ratio
-15.3x
Price/Sales (TTM)
15.0
Price/Cash Flow (TTM)
---
Operating Margin
-104.88%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.